Skip to main content


Our Biotechnology division ranges from molecular diagnostics, to wastewater surveillance, to commercial software that aids clinicians in diagnosing and treating ASD.

Quadrant Laboratories

A new standard of molecular diagnostics, QLabs engages in the research, development and commercialization of molecular diagnostics for certain public health priorities, including Autism Spectrum Disorder (“ASD”), mild-traumatic brain injuries (“mTBI”), Parkinson’s Disease (“PD”) and others. QLabs owns and operates (i) a research and development laboratory with expertise in AI/machine-learning-based discoveries derived from patient phenotypic and genetic/multi-omic next generation sequencing data, and (ii) a 50-state CLIA/CLEP clinical laboratory. QLabs has curated and owns one of the world’s largest biobanks, including over 610,000 saliva specimens from over 160,000 unique individuals; specimens included in this biobank may be appropriate for genetic and multi-omic discovery. These specimens, along with associated de-identified patient data, could allow QLabs to materially expand its research and development pipeline to include ADHD, Depression and Diabetes, among other medical conditions.

Quadrant Life Sciences

Quadrant Life Sciences is dedicated to making life better through the discovery of diagnostic and therapeutic biomarkers for complex medical conditions. Our focus on early detection in autism spectrum disorder, mild traumatic brain injury, and Parkinson’s disease has the potential to transform an individual’s life by enabling quicker access to treatment. Our scientists are developing groundbreaking devices uniting biology and technology to revolutionize how we target and diagnose serious diseases. As part of our ongoing research, we’ve also preserved our specimens for future pipeline expansions, benefitting not only our organization but also other research institutions.

Autism Analytica

AA develops commercial software designed to predict the type and frequency of services needed after a diagnosis of ASD and monitor a child’s progress through treatment over time. AA’s initial offerings will be comprised of (i) software to assist in clinical decision making, inclusive of ten parent/caregiver-completed, clinically validated, measures of a child’s strengths and challenges and the clinical compilation of these results (“Virtual IPM”), and (ii) an objective, clinical diagnostic aid which utilizes vision-tracking technology, proprietary stimuli. AA software is designed for use by clinicians diagnosing children with ASD and behavioral health specialists serving children with ASD.

Virtual IPM Platform

Virtual IPM is an assessment platform designed to inform evaluation and monitor progress in children with ASD and related developmental conditions. Our virtual IPM platform reduces the time and cost associated with evaluating ASD and other neurodevelopmental concerns while improving the quality of treatment through data driven recommendations to clinicians.